Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

Hepatology

Volumn 62, Issue 4, 2015, Pages 1004-1012

  Aqel, Bashar A ^a   Pungpapong, Surakit ^b   Leise, Michael ^c   Werner, K Tuesday ^a   Chervenak, Amy E ^a   Watt, Kymberly D ^c   Murphy, Jennifer L ^b   Ryland, Kristen ^b   Keaveny, Andrew P ^b   Mclemore, Ryan ^a   Vargas, Hugo E ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BILIRUBIN; CREATININE; GROWTH FACTOR; HEMOGLOBIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; DRUG COMBINATION;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHILD PUGH SCORE; CHILD PUGH TURCOTT SCORE; CLINICAL PROTOCOL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RELAPSE; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; VERTIGO; VIRUS LOAD; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

EID: 84942549985     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27937     Document Type: Article

References (27)

1. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010;8:924-933; quiz, e117.
2. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014;39:518-531.
3. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-1192.
4. Pawlotsky JM. New hepatitis C therapies. Semin Liver Dis 2014;34:7-8.
5. Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the Liver Meeting 2014. Gastroenterology 2015;148:468-479.
6. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-287.
7. Manns MP, McCone J, Jr., Davis MN, Rossaro L, Schiff E, Shiffman ML, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int 2014;34:707-719.
8. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-142 e134.
9. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013;19:690-700.
10. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-1679.e3.
11. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
12. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
13. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
14. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. Available at: http://www.hcvguidelines.org. Accessed February 2015.
15. EASL. Recommendations on Treatment of Hepatitis C 2014. (http://www.easl.eu/assets/application/files/easl_recommendations_hcv_2014_full.pdf) 2014. Accessed February 2015.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
17. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015;61:1880-1886.
18. Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015;21:408-409.
19. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015;15(Suppl 2):1-28.
20. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. 65th Annual Meeting of the American Association for the Study of Liver Diseases, November 7-11, 2014, Boston, MA. Hepatology 2014;Abstract LB-6.
21. Bourlière M, Sulkowski MS, Omata M, Zeuzem S, Feld JJ, Lawitz E, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-11, 2014, Boston, MA. Hepatology 2014;Abstract 82.
22. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
23. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
24. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
25. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014;370:1560-1561.
26. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Jr., Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100-107.e1.
27. Janssen Inc. Olysio (simeprevir) prescribing information. Titusville, NJ: Janssen Inc.; 2014.